News Headlines Article

Amgen files for FDA approval for drug to treat dialysis patients
Los Angeles Business Journal

Amgen Inc. said it has filed for approval to sell its drug to treat patients with chronic kidney disease on dialysis. Thousand Oaks-based Amgen(Nasdaq: AMGN) said it submitted a new drug application to the U.S. Food and Drug Administration for etelcalcetide, formerly AMG 416, for the treatment of secondary hyperparathyroidism, a condition that can cause fragile bones, bone pain and organ damage.